Facebook is looking serve as the facilitator of constructive, supportive mental health discussions between friends with today’s release of new features for the social media network and its private messaging service, Messenger.
Timed for release on the World Health Organization’s World Mental Health Day, the company has unveiled a “Let’s Talk” photo filter for Stories that invites peers struggling...
With the staggering shortage of mental health practitioners worldwide, more and more startups are looking for alternative ways to provide patient care. One of the most popular technologies is chatbots.
Now we are seeing one more entrance emerge into that market. On Thursday, Sweden- and UK-based medical device company Flow, best known for its brain stimulation headset, launched a new chatbot...
This morning neurology-focused health startup Flow announced that it landed a $1.5 million investment. This latest round was led by Khosla Ventures.
WHAT THEY DO
The Swedish startup is focused on treating and supporting users with depression. Flow is a two-part system including a brain stimulation headset and a therapy app. When the user puts on the device, it delivers electrical signals to...
Malmö-based medical device startup Flow has landed $1.5m (approximately €1.35m) in funding in a round led by Khosla Ventures, it was announced this week. The new funds will be used to support the European rollout of Flow's brain stimulation headset and therapy app, developed to treat depression, which were launched in the UK and Sweden earlier this year.
“The Khosla Ventures investment will...
This morning, Malmö-based medical device company Flow has announced that it is launching its brain stimulation headset and therapy app to treat depression in the UK.
HOW IT WORKS
Priced at £399, the headset uses transcranial direct current stimulation (tDCS) - a non-invasive treatment using direct electronic currents to stimulate specific parts of the brain in order to help rebalance activity,...
Help from above. The Department of Justice has taken the side of tech-enabled insurer Oscar Health in a federal antitrust suit it filed in November of last year against Florida Blue, Crain’s New York Business reports. While Oscar’s motion for a temporary injunction was rejected by a federal judge back in February, the DOJ filed a statement in April arguing that Florida Blue had incorrectly...
Editor's Note: An original headline for this story contained an error, and has since been corrected.
Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS).
Pear Therapeutics has been developing Pear-...
The acceptability, safety, feasibility and preliminary efficacy of Meru Health’s digital therapeutic for depression will be evaluated in a new two-year investigation conducted by Stanford Medicine and VA Palo Alto Health Care System researchers.
According to a clinicaltrials.gov listing, the research program will enroll older adults aged at least 40 years with depressive symptoms in two studies...
Omada Health will launch new programs for customers with depression and anxiety, the company announced yesterday. The company has entered into a perpetual licensing agreement with Lantern Health, a digital mental health company that shut down its commercial operations last August, and will integrate Lantern’s software into its existing infrastructure. Additionally, a few members of Lantern’s team...
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).
The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
